Abstract
Wnt canonical signaling pathway plays a diverse role in embryonic development and maintenance of organs and tissues in adults. It has been observed that Wnt/β-catenin signaling pathway is involved in the pathogenesis of many carcinomas. Moreover, Wnt/β-catenin pathway has been revealed to be associated with angiogenesis. Wnt canonical pathway signaling has great potential as a therapeutic target. It has been disclosed that some hematological malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, may occur partly due to the constitutive activation of Wnt canonical signaling pathway. This review will summarize the latest development in Wnt canonical signaling pathway and its roles in tumorigenesis and angiogenesis.
Highlights
Wnt canonical signaling pathway acts a significant part in embryonic development and in maintenance of organs and tissues in adults
A lot of studies indicate that Wnt canonical pathway involves in the pathogenesis of a range of disease including many kinds of carcinomas
The incidence of hematological malignancies has been increasing steadily in the world for the past years, but their etiology and pathogenesis has not been well understood involving areas of chromosome aberrations, apoptosis inhibition, abnormal activation of signaling pathways, angiogenesis, et al In this review, we focus on the role of Wnt canonical signaling in carcinomas, especially in hematological malignancies, and disclose potential therapeutic opportunities of this pathway in hematological malignancies
Summary
Wnt canonical signaling pathway acts a significant part in embryonic development and in maintenance of organs and tissues in adults. Since aberrant activation of Wnt canonical signaling pathway is diversely involved in pathogenesis of carcinomas, there has been great interest in developing therapeutics that circumvent it either by inhibiting Wnt mediated transcription or by inactivating the target genes. To further confirm the role of Wnt/b-catenin signaling pathway in tumor angiogenesis and growth, Wnt antagonists WIF1-Fc and sFRP1-Fc were used to treat hepatocellular carcinoma tumors They revealed that these two fusion proteins could inhibit Wnt signaling and exerted potent antineoplastic activity by increasing apoptosis of tumor cells and by impairing tumor vascularization; including reducing the microvessel density, decreasing expression of vascular endothelial growth factor and stromal cell-derived factor-1 [38]. There is great potential that Wnt/b-catenin pathway can act as a therapeutic target of lymphoma and myeloma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
